US Patent 11485710 Heterocyclic amides as kinase inhibitors

Patent 11485710 was granted and assigned to GlaxoSmithKline on November, 2022 by the United States Patent and Trademark Office.

Currently, there are no issues on this topic.

Find more entities like US Patent 11485710 Heterocyclic amides as kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

By using this site, you agree to our Terms of Service.